News
SMMT
3.510
-1.68%
-0.060
Notable Thursday Option Activity: SMMT, MRNA, GME
NASDAQ · 1d ago
Weekly Report: what happened at SMMT last week (0408-0412)?
Weekly Report · 4d ago
Summit Therapeutics Appoints Biotech Veteran to Board
TipRanks · 04/11 20:52
SUMMIT THERAPEUTICS APPOINTS DR. MOSTAFA RONAGHI, RENOWNED EXECUTIVE AND GENOMICIST, TO ITS BOARD OF DIRECTORS
Reuters · 04/11 20:30
Analysts Offer Insights on Healthcare Companies: Avita Medical (RCEL), Summit Therapeutics (SMMT) and Neurocrine (NBIX)
TipRanks · 04/11 11:30
UPDATE 2-Illumina CFO Goswami to depart, former Summit Therapeutics exec Dhingra to succeed
Illumina CFO Joydeep Goswami to depart, former Summit Therapeutics exec Ankur Dhingra to succeed. Gene sequencing company Illumina says he will be succeeded by former Summit executive. Company has reaffirmed its forecast for the first quarter and full-year 2024.
Reuters · 04/09 21:28
UPDATE 1-Illumina CFO Goswami to depart, Summit Therapeutics' Dhingra named successor
Illumina's chief financial officer Joydeep Goswami to leave the gene sequencing company. He will be succeeded by former Summit Therapeutics' Ankur Dhingra. Company reaffirms its forecast for the first quarter and full-year 2024. Illumina's CFO has been with the company since early 2023.
Reuters · 04/09 20:28
CORRECTED-Illumina CFO Goswami to depart, former Summit Therapeutics exec Dhingra named successor
Illumina says chief financial officer Joydeep Goswami to leave the gene sequencing company. He will be succeeded by former Summit Therapeutics exec Ankur Dhingra, Illumina says. Dhingrra is a former executive at the same company, company says.
Reuters · 04/09 20:18
Weekly Report: what happened at SMMT last week (0401-0405)?
Weekly Report · 04/08 09:40
Summit Therapeutics Announces Major Leadership Restructuring
TipRanks · 04/03 20:52
SUMMIT THERAPEUTICS INC - APPOINTED ITS CHIEF OPERATING OFFICER MANMEET SONI TO OFFICE OF CHIEF FINANCIAL OFFICER
Reuters · 04/03 20:43
Commit To Buy Summit Therapeutics At $3, Earn 24.6% Annualized Using Options
NASDAQ · 04/03 16:26
Weekly Report: what happened at SMMT last week (0325-0329)?
Weekly Report · 04/01 09:39
Why Kodiak Sciences Shares Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Kodiak Sciences shares dipped 19.9% to $5.97 on Thursday. The company reported a wider-than-expected fourth-quarter loss. Avalo Therapeutics, Inc. Shares jumped 430% in today's mid-day session. Other stocks moving in the market include RH, Ggoorks and Xilio.
Benzinga · 03/28 18:08
Thursday 3/28 Insider Buying Report: SMMT, EPSN
NASDAQ · 03/28 17:41
Analysts Eye Summit Therapeutics' Ivonescimab As Potential Challenger To Merck's Keytruda in Lung Cancer Treatment
Summit Therapeutics Inc (NASDAQ:SMMT) shows promising potential in two significant phase 3 trials for lung cancer treatment. Stifel initiated coverage on the company with a Buy rating and a price target of $8. The company's main product ivonescimab shows potential to open up a lucrative market worth billions.
Benzinga · 03/26 18:36
Tesla, Krispy Kreme, McCormick And Other Big Stocks Moving Higher On Tuesday
U.S. Stocks were higher on Tuesday. Shares of Tesla Inc (TSLA) rose sharply amid reports suggest Italy has approached the company about electric truck production. The Dow Jones index gained around 50 points in Tuesday's session. Krispy Kreme, Inc. Shares rose 21.3% to $15.10. Praxis Precision Medicines Inc (PRAX) shares jumped 31.9%.
Benzinga · 03/26 14:36
Summit Therapeutics Initiated at Buy by Stifel
Dow Jones · 03/26 08:57
Summit Therapeutics Price Target Announced at $8.00/Share by Stifel
Dow Jones · 03/26 08:57
Stifel Initiates Coverage On Summit Therapeutics with Buy Rating, Announces Price Target of $8
Benzinga · 03/26 08:47
More
Webull provides a variety of real-time SMMT stock news. You can receive the latest news about Summit Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About SMMT
Summit Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of patient, physician and caregiver medicinal therapies. The Company's development candidate is ivonescimab, a potential first-in-class bispecific antibody intending to combine the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects of an anti-VEGF compound into a single molecule. It develops ivonescimab in non-small cell lung cancer (NSCLC), specifically launching Phase III clinical trials in the indications such as ivonescimab combined with chemotherapy in patients with epidermal growth factor receptor (EGFR)-mutated, locally advanced or metastatic non-squamous NSCLC who have progressed after treatment with a third-generation EGFR tyrosine kinase inhibitor (HARMONi), and ivonescimab combined with chemotherapy in first-line metastatic squamous NSCLC patients (HARMONi-3). Its ivonescimab is engineered with Akeso's Tetrabody technology.